English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

FUNDING AND DISCLOSURES BACKGROUND METHODS A Phase 3, Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of IV to Oral Omadacycline to Moxifloxacin for the Treatment of Adult Patients With CABP (The OPTIC Study) Roman Stets, MD, PhD1; Monica Popescu, MD2; Joven Gonong, MD3; Ismail Mitha, MD4; William Nseir, MD5; Andrzej Madej, MD, PhD6; Courtney Kirsch, BS7; Anita Das, PhD7; Lynne Garrity-Ryan, PhD7; Judith N. Steenbergen, PhD7; Amy Manley, BS7; Paul B. Eckburg, MD7; Stephen Villano, MD7; Evan Tzanis, BA7; Paul McGovern, MD7; Evan Loh, MD7 Poster 1883

open forum infectious diseases

A Phase 3 Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of IV to Oral Omadacycline to Moxifloxacin for the Treatment of Adult Subjects with CABP (The OPTIC Study)